Target intelligence / Profile preview

Eukaryotic translation initiation factor 4A1 (eIF4A1)

Target
eIF4A1
Molecular classification
Enzyme, RNA helicase, DEAD box helicase family, Translation initiation factor
01

Overview

Eukaryotic translation initiation factor 4A1 (eIF4A1) is an **ATP-dependent RNA helicase** and a core component of the eIF4F translation initiation complex, which also includes eIF4E and eIF4G. eIF4A1 belongs to the **DEAD box helicase family**, distinguished by their conserved DEAD motif, and is primarily responsible for **unwinding secondary structures** in the 5'-untranslated region (UTR) of mRNAs, facilitating efficient ribosome loading and scanning to locate the start codon for translation[1][2][5][6]. eIF4A1 plays a central role in **cap-dependent translation initiation**. Its expression and function are regulated through interactions with co-factors such as eIF4G, eIF4B, and eIF4H, which enhance its helicase activity[2][4]. eIF4A1-mediated translation is crucial for cell growth and proliferation. Dysregulation or overactivity of eIF4A1 has been implicated in several **cancers**, including acute myeloid leukemia and other hematologic malignancies, by promoting translation of oncogenic mRNAs with complex 5’-UTRs[3]. eIF4A1 is thus considered a viable **anticancer therapeutic target**, with several experimental inhibitors under investigation.

Other names
Eukaryotic initiation factor 4A-IDDX2AEIF4AEukaryotic translation initiation factor 4AIsoform 1
02

Mechanism of action

Inhibition of ATP-dependent RNA helicase activity, impeding mRNA unwinding necessary for translation initiation—targeting eIF4A1 blocks assembly of the eIF4F complex and translation of oncogenic mRNAs

03

Biological functions

Unwinding of mRNA secondary structuremRNA loading onto the 43S pre-initiation complexCap recognition during translation initiationPromoting cell proliferation and growth
04

Disease associations

CancerLeukemiaAcute myeloid leukemiaHematologic cancer
05

Safety considerations

Potential for off-target inhibition of global protein synthesis, leading to toxicity in normal proliferative tissues
06

Interacting drugs

Silvestrol

1 more in the full profile.

07

Biomarkers

Increased eIF4A1 expression may serve as a biomarker for aggressive tumors and cancer prognosis

Beyond the preview

Go deeper on Eukaryotic translation initiation factor 4A1 (eIF4A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic translation initiation factor 4A1 (eIF4A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call